Scleroderma (eBook)

Foreword       Stephen Katz MD, PhD, Director, NIAMSForeword       A personal view: Luke Evnin, PhD, President, SRFPreface           John Varga, MD, Christopher P. Denton, PhD, FRCP, Fredrick M. Wigley, MD Section I. Introduction Chapter 1 – Historical Perspective – Christopher P. Denton, PhD, FRCP, and Carol BlackChapter 2 - Therapeutic evolution: a professor’s view – Frank A. Wollheim, MD, PhD, FRCP                   Section II: Epidemiology, Genetics and ClassificationChapter 3 – Overview: Epidemiology, Genetics and Classification – Christopher P. Denton, PhD, FRCPChapter 4 – Epidemiology and Environmental Risk Factors – Jammie K. Barnes, MD,and Maureen D. Mayes, MD, MPHChapter 5  – Genetic Factors – Yannick Allanore, MD, PhD, and Filemon K. Tan, MD, PhDChapter 6 – Disease Subsets in Clinical Practice  – Robyn Therese Domsic, MD, MPH,and Thomas A. Medsger, Jr., MDChapter 7 – Evolving Concepts of Diagnosis and Classification – Lorinda Chung, MD, MS, Jaap Fransen, MD, and Frank H.J. Van den Hoogen, MD, PhDChapter 8 – Disease Classification using Molecular Signatures  – Michael L. Whitfield, PhD, and Robert Lafyatis, MDSection III: Scleroderma in ChildrenChapter 9 – Juvenile Localized Scleroderma – Francesco Zulian, MDChapter 10 - Juvenile Systemic Scleroderma - Ivan Foeldvari, MDSection IV:  Other Fibrosing Skin ConditionsChapter 11 – Scleroderma Mimics –Laura K. Hummers, MD, ScMChapter 12 - Localized Forms of Scleroderma in Adults – Amy E. Gilliam, MD, and Anita C. Gilliam, MD, PhDChapter 13 - Nephrogenic Systemic Fibrosis – Peter J. Wermuth, PhD, and Sergio A. Jimenez, MDSection V: Pathogenetic Basis Chapter 14 - Overview: Integrated Pathogenesis – John Varga, MDChapter 15 - Immunological Mechanisms – Francisco Boin, MD, and Carlo Chizzolini, MDChapter 16 - Innate Immunity – Keith B. Elkon, MD, and Julia J. Rhiannon, MD, MSWChapter 17 – Autoantibodies in Pathogenesis – Kimberly Doering, BS, and Antony Rosen, MB ChB, BSc (Hons)Chapter 18 - The Clinical Aspects of Autoantibodies - John D. Pauling, BMBS, MRCP, and Neil McHugh, MB, ChB, MD, FRCP, FRCPathChapter 19 – Mechanisms of Vascular Disease – Bashar Kalaheh, MD, and Mary Jo Mulligan-Kehoe, PhDChapter 20  - Vascular Biomarkers – Laura K. Hummers, MD, ScM Chapter 21 – Mechanisms of Fibrosis – John Varga, MDChapter 22 – Fibrosis: Insights from the stiff skin syndrome – Elizabeth E. Gerber, BS, and Harry C. Dietz, MDChapter 23 - Biomarkers of Fibrosis – Christian Beyer, MD, Oliver Distler, MD, and Jörg H.W. Distler, MDChapter 24 – Overview of Animal Models – Christopher P. Denton, PhD, FRCP, and Robert Lafyatis, MDSection VI: Cardiovascular Manifestations and ManagementChapter 25 – Overview: Cardiovascular Manifestations and Management – Fredrick M. Wigley, MDChapter 26 – Raynaud Phenomenon  – Arianne Herrick and Fredrick M. Wigley, MDChapter 27 – Nailfold Capillaroscopy – Maurizio Cutolo, MD and Vanessa Smith, MD, PhD 28SystemicVascular Disease , MD, PhD, MD, FRCP Chapter 29 – Scleroderma Renal Crisis – Christopher P. Denton, PhD, FRCP, and Virginia Steen, MDChapter 30 – Cardiac Involvement –Sanjiv J. Shah, MD, and André Kahan, MD, PhDChapter 31 – Erectile Dysfunction – Edward V. Lally, MD, Arthur L. Burnett, MD, MBA, FACS, and Trinity J. Bivalacqua, MD, PhDSection VII: Pulmonary manifestations and management Chapter 32 – Overview: Pulmonary manifestations and management – Christopher P. Denton, PhD, FRCPChapter 33 – Clinical Assessment of Lung Disease – Greg J. Keir, MBBS, FRACP, Richard M. Silver, MD, and Athol U. Wells, MD, FRCPChapter 34 – Computerized Tomography of Interstitial Lung Disease – Athol U. Wells, MD, FRCP, and Jonathan Goldin MD, PhD, FRCRChapter 35 – Treatment of interstitial lung disease – Dinesh Khanna, MD, MS, and Donald P. Tashkin, MDChapter 36 – Clinical Assessment of Pulmonary Hypertension – Harrison W. Farber, MD, Michael York, MD, Eric Hachulla, MD, PhDChapter 37 – Treatment of Pulmonary Hypertension –Todd H. Kolb, MD, PhD, and Paul M. Hassoun, MDChapter 38 – Complex Challenges of Pulmonary Hypertension – John Gerard Coghlan, MD, FRCPSection VIII: Gastrointestinal manifestations and managementChapter 39– Overview: Gastrointestinal Manifestations and Management - Seth Sweetser, MD, and Michael Camilleri, MDChapter 40 – Upper Gastrointestinal Tract - John O. Clarke, MD, and Ikuo Hirano, MDChapter 41 – Small and Large Intestinal Involvement - Philip J. Clements, MD, MPH, Terri R. Getzug, MD, and Dinesh Khanna, MD, MSSection XIX: Skin, musculoskeletal and other complications Chapter 42 - Evaluation and Management of Skin Disease – Noëlle Starr Sherber, MD, FAADChapter 43 – Skeletal Muscle Involvement – Andrew L. Mammen, MD, PhDChapter 44 - Tendons, Joints and Bone – Jérôme Avouac, MD, PhD, and Yannick Allanore, MD, PhDChapter 45 – Pregnancy – Virginia Steen, MD, and Eliza F. Chakravarty, MD, MSChapter 46 - Overlooked Manifestations– Ami A. Shah, MD, MHSSection X:  Disease-modifying strategiesChapter 47 –Principles of ManagementD. , MD, MPH Chapter 48 - Immunomodulatory Therapies – Jacob M. van Laar, MD, PhDChapter 49 - Cell-Based Therapies – Alan G. Tyndall, MD, FRACP, Rheumatology FMH, and Keith M. Sullivan, MDChapter 50 - Investigative Approaches to Drug Therapy – Voon H. Ong, PhD, MRCP, and Christopher P. Denton, PhD, FRCPChapter 51 – Complementary and alternate medicine approaches – Judy A. Fulop, MD, MS, FABNO, and John Varga, MD Chapter 52 - Physical and occupational therapy– Luc Mouthon, MD, PhD, and Janet L. Poole, PhD, OTR/L Chapter 53 – Evaluation and Management of Psychosocial Issues – El-Baalbaki Ghassan, PhD, Lisa Jewett, BA, MSc, Jennifer A. Haythornthwaite, PhD, and Brett D. Thombs, PhDSection XI: Outcome assessmentChapter 54 - Issues in Clinical Trial Design– Suzanne Kafaja, MD, Daniel E. Furst, MD, and Janet E. Pope, MD, MPH, FRCPCChapter 55 - Measuring Disease Activity– Dinesh Khanna, MD, MSChapter 56 – Patient Reported Outcomes – Monique Hinchcliff, MD, and David Cella, PhD